Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors

Completed · Phase 1

Conditions studied: Advanced Solid Tumors

In brief

This is an open-label, study of MEDI9090 to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of MEDI9090 in adult subjects with advanced solid tumors.

Key facts

Study ID

NCT02900157

Run by

MedImmune LLC

People needed

42

Starts

2016-08-09

Expected to finish

2020-01-23

Last updated by the study team

2021-01-14

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male and female subjects
• 18 years and older
• Must have histologic documentation of advanced solid tumors
• Must have received and have progressed, are refractory or, intolerant to standard therapy and must not have a curative therapy option

You may not qualify if…

• Concurrent enrollment in another clinical study
• Prior participation in clinical studies that include durvalumab alone or in combination
• Concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment

Where it is running

• Research Site — Scottsdale, Arizona, United States
• Research Site — Los Angeles, California, United States
• Research Site — Denver, Colorado, United States
• Research Site — Huntersville, North Carolina, United States
• Research Site — San Antonio, Texas, United States
• Research Site — Kōtoku, Japan
• Research Site — Sapporo, Japan
• Research Site — Sunto-gun, Japan

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.